Pfizer’s Dalbavancin “Approvable”
FDA issued an "approvable" letter for Pfizer's lipoglycopeptide antibiotic dalbavancin Sept. 21, the agency said
FDA issued an "approvable" letter for Pfizer's lipoglycopeptide antibiotic dalbavancin Sept. 21, the agency said